Objective:
Introduction
RA is a complex autoimmune disease of unknown aetiology involving chronic inflammation of the peripheral joints leading to cartilage destruction and bone erosion.
The major genetic factor contributing to susceptibility to RA across species is the major histocompatibility complex (MHC), in humans designated human leukocyte antigen (HLA). CIA is an animal model resembling human RA, which is in mice strongly associated with the positionally identified MHC class II Aß gene (1). Interestingly, the RA associated MHC class II molecules expressed in the mouse system allow the development of CIA, thereby responding to the same CII peptide as Aq expressing mouse strains (2). A hallmark of human RA is the development of autoantibodies directed against the Fc portion of immunoglobulins (RF), antibodies directed against citrullinated peptide antigens (ACPA) and in a subset of patients anti-type II collagen antibodies (AC2A). In fact, the development of ACPA is a classification criterium for RA diagnosis and both ACPA and RF development have a high predictive value for later onset of RA (3). A close association between ACPA and certain MHC alleles strongly indicate specific T cell driven autoimmune responses preceding development of RA. However, despite the high value of RF and ACPAs as prognostic biomarkers for severe erosive arthritis, it has been difficult to demonstrate a direct link between autoantibody development and RA pathogenesis (4). In turn, AC2A antibodies are less frequent and there is no evidence that they are occurring as early as ACPA or RF (5). These antibodies can be detected around disease onset and several lines of evidence argue for their pathogenic importance. In CIA, AC2As are a driving force in disease pathogenesis, illustrated by the fact that passive transfer of AC2A from CIA immunised mice into naïve hosts elicits a similar disease (6, 7). Markedly, the same results have been obtained across species after transfer of the AC2A containing Ig fraction of a RA patient into mice (8).
Moreover, in CII immunised mice, the B cell response is essentially directed towards conserved triple helical CII epitopes (9). Similar fine specificity has been observed in human arthritis patients strengthening the role of CIA as a relevant model for pathogenic B cell response in RA patients (10, 11). Antibodies specific for these major epitopes induce arthritis in mice upon single transfer or in combination further supporting a pathogenic role of anti-CII autoimmunity in RA (12). AC2A is also associated with the MHC class II region in humans, though not as strongly as either ACPA or RF. However, little is known about the contribution of non-MHC genes controlling autoantibody formation against CII in RA. So far, a candidate gene approach associated the R620W polymorphism in Ptpn22 in conjunction with HLA-DRB1 alleles with C1 directed humoral immune responses in RA patients (13).
Animal models like CIA provide a unique opportunity to study the genetics of antibody response systematically, as large cohorts of mice can be phenotyped under stable environmental conditions. Recently, heterogeneous stock mice have been successfully introduced to fine map known QTLs and high-resolution genome wide mapping of a diverse range of quantitative phenotypes. Moreover, HS derived mouse cohorts have been used to map the genetic control of arthritis severity in an antigen dependent model as well as a mouse model based on passive transfer of arthritogenic autoantibodies (14, 15) . So far the contribution of non-MHC alleles to genetic susceptibility of autoantibody formation towards CII in human RA, as well as its murine counterpart, is incompletely understood. However, resolution of QTL controlling autoantibody production in CIA and the identification of the underlying polymorphisms may result in identification of novel therapeutic targets for human RA. Here we report a detailed global genetic analysis of the antibody profile during CIA development using our previously described heterogeneous stock derived cohort of mice (14) .
Materials and Methods

Animals and arthritis induction
The animals used for the CIA experiment, the experimental procedures regarding CIA induction as well as the details concerning production of the HSxBQ cohort including a detailed breeding scheme have been described in detail in Ahlqvist et al. (14) . In brief, HS mice known as the Northport stock derived from 8 common inbred strains A/J, AKR/J, BALB/cJ, CBA/J, C3H/HeJ, C57BL/6J, DBA/2J and LP/J originated in R.
Hitzemann's lab and have been backcrossed in an F3 cross with C57BL/10.Q (hereafter BQ) and mice expressing the CIA susceptible MHC class II allele Aq were selected.
Three batches comprising a total number of 1764 mice were produced, immunized and monitored for CIA development. All mice were immunized with 100 µg rat type II collagen (rCII) emulsified in 50 µl IFA (Difco, Detroit, MI, USA) containing 25 µg Mycobacterium butyricum at day 0. Thereafter, they were followed for seven weeks for development of clinical arthritis. Details concerning incidence, onset and disease severity are included in the supplement. (supplementary table 1 
Serum sampling
Of 1764 animals 1640 have been bled from the retro-orbital venous sinus into heparin containing tubes (10 U/ml). Blood samples were collected prior to CIA onset (day 14), as well as at the peak of the disease seven weeks (day 50) post rCII immunization upon termination of the experiment. Cia9 congenic mice were bled 35 days after initial immunization. Plasma has been separated from erythrocytes after centrifugation for 20 minutes at 4000 rpm and was frozen at -20°C until it was assayed.
For detection of AC2A NUNC Maxisorb immuno plates (NUNC, Roskilde, DEN) were coated with CII (10 µg/ml) in carbonate/bicarbonate buffer (pH = 9.6) over night at 4°C and subsequently blocked with 2% bovine serum albumin (BSA) (Sigma, St. Louis, MO, USA). Diluted serum samples were added and incubated at 4°C over night.
Immunoglobulin Ig, IgG1 and IgG3 antibodies were measured using polyclonal goat derived horseradish peroxidase (HRP) conjugated secondary antibodies anti-Ig, -IgG1, and -IgG3 (Southern Biotechnologies Associates, Birmingham, AL, USA).
AC2A and ACPA peptide ELISA
Synthesis of collagen peptides was previously described elsewhere (10). The citC1 peptide was obtained from (GL Biochem, Shanghai, China). For measurement of peptide directed antibody responses Maxisorb immuno plates (NUNC, Roskilde, DEN) were coated with triple helical peptides (U1, J1, C1, citC1) at 5 µg/ml in PBS over night at 4°C and subsequently blocked with 2% BSA (Sigma, St. Louis, MO, USA). Plates were washed and diluted serum samples were added and incubated at 4°C over night. All antibody titers have been measured using HRP conjugated anti-κ light-chain specific secondary antibody (clone 187.1 -Southern Biotechnologies Associates, Birmingham, AL, USA). All peptides were investigated at both time points (day 14, day 50) except the J1 peptide, which was only assessed at day 50.
RF ELISA
RF detection using anti-κ light-chain specific antibodies has been outlined elsewhere (17) . Briefly, all plates were coated with rabbit IgG (10 µg/ml) (Sigma, St. Louis, MO, USA). After blocking with 2% BSA all plates were washed and diluted serum samples added and incubated at 4°C over night. All antibody titers have been measured using HRP conjugated anti-κ light-chain specific secondary antibody (clone 187.1 -Southern Biotechnologies Associates, Birmingham, AL, USA).
Plate development
All ELISA plates were developed after addition of ABTS: 2,2'-azino-bis-[3-ethylbenzothiazoline-6-sulphonic acid] (Roche, Mannheim, Germany). A pool of serum samples has been used as standard and all antibody titers were measured as arbitrary concentrations. Anti-CII IgG isotype (IgG1, IgG3) and anti CII-peptide antibody titers (C1, U1, J1) were quantified using defined affinity purified antibodies from CIA immunised DBA/1J mouse sera. RF and citC1 titers were not quantified due to the lack of a similarly defined standard.
Statistical Analysis:
The statistical analysis of the HS population for CIA has been extensively outlined earlier. Before analysis all antibody titers were normalized using Box-Cox transformations.
Single locus mapping -The haplotype structure of the mice was inferred using the haplotype reconstruction method HAPPY, thereby utilizing founder strain genotypes to calculate the probability F Li (s,t) that a locus interval originates from founder strains s,t.
(18). Evidence of a QTL was calculated for each interval by fitting the regression model
is the phenotype effect due to strains s,t at the locus T. A 5% genome-wide significance threshold was determined by 200 permutations of the dataset. Age, sex and batch were used as covariates in all analyses.
Resample model inclusion probability (RMIP) -The complex family structure of heterogeneous stock derived mouse populations has been shown to increase the risk of false positive findings. To address this issue a resampling based multi-locus modeling method has been developed (19). RMIP for loci were calculated by subsampling (N=60, subsample size 80%) with forward selection, adding loci to the model as long as the addition generated a p-value less than 5% genome-wide significance threshold (adjusted to the subsample size) as described previously (19). All loci were included in the model Correlation between antibody titers and disease parameters was performed by logistic or linear regression. The antibody titers were ln-transformed before analysis and sex, age and experiment batch were included as covariates.
Results
When we investigated the Ig response against CII and against CII peptides we found for all time points that sick animals display significantly higher antibody titers than healthy ones, regardless of which serological parameter was assessed ( figure 2A, supplementary   figure 1 ). We also observed a significant increase in antibody titers over time during CIA for all serological parameters except AC2A of IgG3 isotype, which showed significantly higher titers on day 14 than on day 50 ( figure 2A, supplementary figure 1 ).
QTL mapping of anti-collagen IgG antibody response
As in our previously published study concerning QTL mapping of CIA in HSxBQ mice, we started out using the HAPPY algorithm inferring the founder haplotype structure in any given interval based on the genotype of the adjacent markers. We investigated the genetic control of anti-CII -Ig, -IgG1, which represents a T cell dependent response against protein antigens constituting the major component of the Ig fraction and -IgG3, representing a T cell independent response against sugar moieties of polysaccharide antigens. We identified 58 sometimes overlapping loci for these three phenotypes (AC2A When we examined the genes in the associated interval, we identified C1q as a likely candidate. This notion was supported by the strain distribution of coding nonsynonymous SNPs within the C1q gene cluster that follow the same pattern as the haplotypes that correlate with low RF levels ( figure 4B and supplementary table 3 ). For RF and CII-specific epitope responses (C1, U1, J1) we found an association with the IgH locus on chr. 12 between 109 Mb and 120 Mb for both time points during CIA development (-LogP: 6.2-156.3; range RMIP: 0.50-1.0) (figure 2B). In fact, the IgH locus is the only locus significantly associated with J1 response on day 50 in HSxBQ mice.
Next, we compared the genetic control of antibody response against the major B cell epitope C1 (CII (359-370) ) and its citrullinated form citC1 (ACPA), which are both also recognized in human RA (21). Here, we found a distinct genetic regulation pattern for the citC1 (ACPA) response compared with C1. This is shown both by the low correlation antibody responses against the C1 and citC1 epitope (r 2 = 0.06 (day 14); r 2 =0.15 day 50 linear regression) and by the genetic mapping ( figure 1C, 1D and figure 2B ). In fact we detected several loci uniquely controlling either C1 or citC1 response at both time points.
For example, the C1 response maps to the IgH locus, whereas only a weak association (range RMIP < 0.25) was detected for citC1 ( figure 2B ).
Correlation between CIA and anti-collagen antibody levels
All antibody isotypes measured at day 14 were associated with an increased risk of developing CIA ( figure 5A ). Of the epitope specific antibody titers, antibodies towards the C1 epitope were the strongest predictor of disease. ACPAs directed towards the citC1 epitope also showed a significant association with incidence of the disease, but the increase in risk was comparatively small ( figure 5A and 5B). This was also the case for RF ( figure 5A and supplementary 
Comparison between QTL mapping of antibody response and CIA
Finally, we assessed the shared genetic control of anti-CII antibody response and CIA development, by comparing the loci that were most strongly associated with CIA in our previous study (14) . We used C1 and IgG1 levels, which are the best predictors of disease and found that two CIA loci overlap directly with loci controlling these phenotypes ( figure 1A and 1B) . One of these loci maps to the telomeric region of murine chromosome 1 to a locus previously described as Cia9, with the peak marker for CIA severity, onset and incidence being located close to the Fc receptor (FcR) gene cluster (figure 2B, figure 3A ) (22). In order to confirm these findings we performed a CIA experiment in a 10 Mb NOD derived congenic fragment, that includes the previously described Cia9 region (supplementary figure 2) (23). We found that upon immunization with rCII CIA severity as well as AC2A of IgG1 and IgG3 isotype are strongly increased in these mice compared to BQ controls thus providing further evidence of the usefulness of heterogeneous stock mice for fine mapping of QTLs ( figure 3A, 3C and 3D ).
The other disease locus is located on chromosome 12 at around 77 Mb with the peak marker mapping close to Esr1 gene (estrogen receptor alpha) (table 3). The strongest CIA locus, which was found on chromosome 2 mapping to the Hc gene (complement component 5) did not show an association with neither IgG1 nor C1 response (figure 5B).
Discussion
With our study we provide a comprehensive genetic analysis of clinically relevant autoantibody responses during CIA development using a mixed inbred-outbred HS derived mouse cohort.
Rheumatoid factor
Antibodies against the Fc portion of Ig were already described 60 years ago and have been used as a serological marker to classify human RA according to the ACR (24). Their role in RA susceptibility has long been debated and despite the fact that RF can be detected prior to disease onset, evidence for a clear role in RA pathogenesis is lacking.
We found that circulating levels of RF prior to disease onset, slightly increase the risk of developing CIA. The locus with the highest association for RF was detected on chromosome 4. We examined the genes in the associated interval and identified C1q as a likely candidate gene, which is supported by single marker association of closely located
SNPs. The importance of the classical pathway of complement activation for antibody production is illustrated by the fact that mice deficient in either one of its components 
ACPAs
In addition to the RF response we investigated the ACPA response in our mice. ACPAs directed against cyclic citrullinated antigens (CCP) are a highly RA specific biomarker and have been successfully introduced into the clinic within the last decade (31). They are also part of the revised ACR and EULAR criteria for RA diagnosis (32). However, opposite to human RA, specific anti-CCP antibodies are not present in murine CIA (33, 34). When we analyzed ACPA response against the citC1 epitope, which is also present in RA patients, we found that in CIA similarly to the human situation these antibodies predict disease. Moreover, we showed that at the peak of the disease citC1 antibody levels correlate with disease severity. This is in line with our previous observations concerning the ACC4 monoclonal antibody specific for the citC1 epitope, which is not arthritogenic itself, but aggravates arthritis severity after co-administration with the M2139 antibody in subarthritogenic dose in the collagen antibody induced arthritis model, which mimicks the effector phase of RA (35). Nevertheless, C1 antibodies have a much higher predictive value for CIA development and correlate better with disease severity during the late stage of CIA than citC1 specific ACPAs, probably reflecting the fact that CII autoimmunity is the driving factor in CIA following immunization, whereas in human RA it occurs only in a subset of patients reacting to modified cartilage CII (2).
Immunoglobulin heavy chain locus
Mapping IgG3 response does not seem to be controlled by the FcR locus, probably due to the fact that this isotype binds only weakly if at all to Fcgr1 (46, 47) . On the other hand the Traf1-C5 (complement component) locus, which is highly associated with arthritis development across species, was not associated with antibody development (22, 48) . This finding supports experimental data from rodent animal models of arthritis, where C5 deficiency was associated not only with protection in CIA but different arthritis models based on passive transfer of arthritogenic antibodies outlining its importance for mediating effector mechanisms in murine arthritis pathogenesis (49, 50) .
In conclusion, we report a comprehensive genetic analysis of clinically relevant autoantibody response during CIA development using a HS derived cohort of mice. Our data indicates complex genetic control of AC2A of different isotypes, ACPA and RF illustrating that non-MHC genes determine antibody specificity with particular importance of the IgH locus. Our study demonstrates the potential of HS stock mice for high resolution mapping of autoantibody controlling QTLs, thereby facilitating a more rapid identification of candidate genes as well as candidate polymorphisms that can be further exploited to define novel targets for therapeutic intervention. We also found that some CIA and anti-CII antibody controlling loci like the FcR or the Esr1 locus are overlapping and thereby co-segregate within the mouse genome, indicating that the underlying genes were co-selected during the evolution of murine inbred strains. Antibody titers between healthy and sick animals are always significantly different, with a p<0.0001. For the exception of IgG3, all titers are significantly higher on day 50, compared to day 14. ** for observed p<0.01 and *** for p<0.0001.
